rheumatoid arthritis | Research | Treatment | 10 pages | source: Annals of the rheumatic diseases | Added Aug 05, 2019
Is a combination of tocilizumab and methotrexate more effective than tocilizumab alone?
This study compared the safety and effectiveness of treatment with tocilizumab (TCZ, Actemra) on its own or in combination with methotrexate (MTX, Trexall) in rheumatoid arthritis (RA) patients who have a poor response to MTX. The study concluded that TCZ and MTX together were more effective than TCZ alone
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Care & Research | Added Aug 03, 2019
Long-term treatment with baricitinib - an analysis of the long-term safety and effectiveness
This study investigated the safety and effectiveness of long-term treatment with baricitinib (Olumiant) in rheumatoid arthritis (RA).
They found that this drug was effective and well tolerated alone or in combination with methotrexate (MTX).
rheumatoid arthritis | Research | Treatment | 10 pages | source: Annals of the rheumatic diseases | Added Aug 01, 2019
Combining therapies for very early rheumatoid arthritis
This study examined the combination of abatacept (Orencia) with methotrexate (Trexall) in achieving and maintaining remission in patients with very early rheumatoid arthritis (RA). Researchers concluded that combination therapy is more effective than each treatment alone in achieving remission in very early RA.
rheumatoid arthritis | Research | 10 pages | source: Annals of the rheumatic diseases | Added Jul 30, 2019
Examining the presence of RA in patients with and without the presence of certain antibodies in the blood
This study compared the severity of inflammation in rheumatoid arthritis (RA) patients with (seropositive) and without (seronegative) certain antibodies in their blood. The authors concluded that seronegative patients had higher levels of inflammation than seropositive patients.
diabetes mellitus | Research | 10 pages | source: Diabetes Research and Clinical Practice | Added Jul 29, 2019
SGLT-2 inhibitors and lower limb amputation risk in people with type 2 diabetes
This study wanted to find out if treating type 2 diabetes with SGLT-2 inhibitors increases the risk of disease in blood vessels or the risk of amputation of the feet. The study found that treating type 2 diabetes with certain SGLT-2 inhibitors such as canagliflozin (Invokana) may be associated with an increased risk of disease in the blood vessels, and the risk of amputation of the feet.
rheumatoid arthritis | Research | 10 pages | source: Bone | Added Jul 28, 2019
Is there a link between frailty and fracture risk in rheumatoid arthritis?
This study investigated if there is a link between frailty and fracture (breaking of a bone) risk in rheumatoid arthritis (RA).
They found that patients with higher frailty were more likely to have bone fractures.
rheumatoid arthritis | Research | 22 pages | source: Arthritis Care & Research | Added Jul 25, 2019
Use of methotrexate in daily practice in the United States
The authors examined the patterns of use of methotrexate: dose administered, method of administration, and duration of treatment.
rheumatoid arthritis | Research | 9 pages | source: Rheumatology International | Added Jul 23, 2019
Interleukin-34 can predict joint damage progression in patients with rheumatoid arthritis
This study investigated whether the levels of interleukin-34 can predict joint damage in patients with rheumatoid arthritis (RA).
rheumatoid arthritis | Research | 6 pages | source: PLOS ONE | Added Jul 21, 2019
Can blood markers predict rheumatoid arthritis-associated interstitial lung disease?
This study investigated whether specific blood markers can predict if patients will be affected by rheumatoid arthritis-associated interstitial lung disease (RA-IDL).
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Jul 19, 2019
Abatacept – what is the safety profile in rheumatoid arthritis treatment?
This study investigated the safety of abatacept (Orencia) compared to other disease-modifying anti-rheumatic drugs (DMARDs).
They found that this treatment was well tolerated and had a similar safety profile to other DMARDs.
